Vi kan også sige 2500 nu og 5000 senere...Roche har gjort det efter den opskrift flere gange. Big Phama skriger efter afløsere til alle de stoffer, der går af patent i de kommende år.
We are very pragmatic and realistic in our approach to partnerships. If it makes sense
and we can find one strategic partner that can maximise one or several of our
candidates then we will do that otherwise deal making will be determined by finding
the right partner for the right asset.
JNJ har nærmest valideret duoboduplatformen forleden og Genmab kan fremvise kliniske resultater fra pipelinen. Vi ved CD20/CD3 og DR5/DR5 kan blive store.
Det kan man vel også få ved at købe det hele og lade dem være som et selvstændigt selskab. Ikke at jeg ønsker at Genmab bliver overtaget lige nu. Dertil er kursen for lav.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
